文献速递白血病

ENESTop 5年更新:二线尼洛替尼治疗慢性髓性白血病无治疗缓解的长期结局

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
PubMed 文献 · Leukemia · 2021-05-12

ENESTop研究评估了从伊马替尼换用尼洛替尼后达到持续深度分子学缓解的慢性期CML患者的无治疗缓解(TFR)。126例患者尝试TFR,48周时57.9%(73/126)处于TFR,5年时42.9%(54/126)仍处于TFR。停药后失去MMR或确认失去MR4而重启尼洛替尼的患者中,98.3%重获MMR、94.9%重获MR4、93.2%重获MR4.5;无疾病进展或CML相关死亡,但随尼洛替尼暴露时间延长心血管事件累积增加。

要点

  • 二线尼洛替尼后5年TFR率为42.9%,低于48周时的57.9%。
  • 重启尼洛替尼后多数患者可重获深度分子学缓解。
  • TFR期间不良事件率下降,但重启后心血管事件累积增加。

核心结论

  • 二线尼洛替尼治疗后的TFR具有持久性和安全性,但重启治疗时需仔细管理心血管风险。

研究设计与样本

  • ENESTop研究为多中心单臂研究,纳入接受≥3年TKI治疗且仅在换用尼洛替尼后达到持续深度分子学缓解的慢性期CML患者,1年尼洛替尼巩固后126例尝试TFR。

主要发现

  • 48周主要分析时57.9%(73/126)处于TFR,5年时42.9%(54/126)处于TFR。
  • 48周后离开TFR期的患者中,58%(11/19)未失去分子学缓解,因其他原因停药。
  • 59例因失去MMR或确认失去MR4而重启尼洛替尼,98.3%重获MMR,94.9%重获MR4,93.2%重获MR4.5。
  • 5年TFR期间总体不良事件率下降,重启尼洛替尼者心血管事件随暴露时间累积增加。
  • 未报告疾病进展或CML相关死亡。

临床怎么用

  • 对二线尼洛替尼后达到持续深度分子学缓解的慢性期CML患者,可考虑尝试TFR并长期监测。
  • TFR期间需定期监测分子学缓解,失去MMR或确认失去MR4时重启尼洛替尼。
  • 重启尼洛替尼前及治疗中应仔细评估和管理心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) in chronic phase who had received ≥3 years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after switching from imatinib to nilotinib. After 1-year nilotinib consolidation, 126 patients attempted TFR. At 48 weeks (primary analysis), 57.9% (73/126) were in TFR. In the present analysis at 5 years, 42.9% (54/126) were in TFR. Since the 48-week analysis, among patients who left the TFR phase, 58% (11/19) did not have a loss of molecular response and discontinued for other reasons. Of the 59 patients who reinitiated nilotinib upon loss of major molecular response (MMR) or confirmed loss of MR4, 98.3% regained MMR, 94.9% regained MR4, and 93.2% regained MR4.5. Overall adverse event rates decreased over the 5 years of TFR. In patients reinitiating nilotinib, there was a cumulative increase in cardiovascular events with longer nilotinib exposure. No disease progression or CML-related deaths were reported. Overall, these results confirm the durability and safety of TFR for patients receiving second-line nilotinib. Cardiovascular risk should be carefully managed, particularly when reinitiating treatment after TFR.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hughes TP, Clementino NCD, Fominykh M, et al. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 2021. PMID: 33980976. doi:10.1038/s41375-021-01260-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。